Chest
-
Slide PresentationsPRESENTED ON: Sunday, March 23, 2014 at 04:15 PM - 05:15 PMPURPOSE: QVA149 is a once-daily dual bronchodilator containing a fixed-dose combination of the long-acting β2-agonist (indacaterol) and long-acting muscarinic antagonist glycopyrronium, for the treatment of COPD. We evaluated the overall rate of exacerbations and the health status with QVA149 in comparison with glycopyrronium and tiotropium. ⋯ Jadwiga Wedzicha: Consultant fee, speaker bureau, advisory committee, etc.: JW has received speaking fee and/or for advisory boards from GlaxoSmithKline, AstraZeneca, Novartis, Bayer, Boehringer Ingelheim, Nycomed. Chiesi and Respifor as well as travel reimbursements from Boehringer Ingelheim. JW has received research grants from GlaxoSmithKline, AstraZeneca, Chiesi and Novartis. Joachim Ficker: Consultant fee, speaker bureau, advisory committee, etc.: Dr. Ficker has received speaker fees from AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Pfizer, Nycomed, Almirall, Berlin-C hemie, Takeda and Novartis, consulting fees from AstraZeneca, Boehringer Ingelheim, and Novartis. Angel FowlerTaylor: Employee: The author is an employee of Novartis Pharmaceuticals Corporation Peter D'Andrea: Employee: The author is an employee of Novartis Pharmaceuticals Corporation Christie Arrasate: Employee: The author is an employee of Novartis Pharmaceuticals Corporation Hungta Chen: Employee: The author is an employee of Novartis Pharmaceuticals Corporation Donald Banerji: Employee: The author is an employee of Novartis Pharmaceuticals CorporationClinical trial results of QVA149, combination of two approved products indacaterol and glycopyrronium, will be presented, QVA149 is in the late stage phase 3 trials prior to approval.
-
COPD PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Indacaterol is an ultra-long-acting beta-adrenoceptor agonist which needs to be taken once a day, licensed only for the treatment of chronic obstructive pulmonary disease (COPD). It is delivered as an aerosol formulation through a dry powder inhaler. A year-long, placebo-controlled trial published in July 2010 suggests indacaterol may be significantly more effective than twice-daily formoterol in improving FEV1. There were some reductions in the need for rescue medication, but these were not significantly different; nor was there any difference in the rate of exacerbation between the 2 active treatments. We looked at our data regarding the use of Indacaterol in a tertiary care set up. This is a real life experience looking at how Indacaterol influences clinical (MRC dyspnoea scale) and physiological (Spirometry) parameters and exacerbation episodes. ⋯ The following authors have nothing to disclose: Raja Dhar, Sanjit Ray ChaudhuriNo Product/Research Disclosure Information.
-
Surgery Case Report Posters ISESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Bronchogenic cysts are developmental anomalies of the ventral foregut arising from abnormal budding of the primitive tracheobronchial tree. Usually they acquire an intra-thoracic location primarily mediastinal or intraparenchymal, though atypical locations including cervical, intradiaphragmatic, interatrial septum and retroperitoneal have been reported. We present an extremely rare, aberrant location of a bronchogenic cyst within the thymic tissue that was minimally resected with robotic assistance. ⋯ The following authors have nothing to disclose: Maria Siddiqui, Adnan Al-Ayoubi, Sadiq Rehmani, Faiz BhoraNo Product/Research Disclosure Information.
-
TransplantationSESSION TYPE: Slide PresentationsPRESENTED ON: Sunday, March 23, 2014 at 12:15 PM - 01:15 PMPURPOSE: In order to identify the characteristics of late-onset non-infectious pulmonary complications (LONIPCs) in children who have undergone allogeneic hematopoietic stem cell transplantation (HSCT), we retrospectively evaluated the incidence, characteristics, and outcomes of LONIPCs in these patients. ⋯ The following authors have nothing to disclose: Jong-seo Yoon, Hwan Soo Kim, Jae Wook Lee, Yoon Hong Chun, Nack Gyun Chung, Hyun Hee Kim, Bin Cho, Hack Ki Kim, Joon Sung LeeNo Product/Research Disclosure Information.
-
COPD Comorbidity PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: The Baseline (BDI) and Transition Dyspnea Index (TDI) are interview-based multidimensional instruments to assess breathlessness in patients with COPD. However, BDI/TDI interviewer process may introduce bias in the interpretation, leading to more variability in results. Innovative self-administered computerized (SAC) versions of the BDI/TDI were developed and validated for the BLAZE study which allows patients to provide direct ratings of breathlessness based on activities of daily living. ⋯ Anthony D'Urzo: Consultant fee, speaker bureau, advisory committee, etc.: AD has received research, consulting and lecturing fees from GlaxoSmithkline, Sepracor, Schering Plough, Altana, Methapharma, AstraZeneca, ONO pharma, Merck Canada, Forest Laboratories, Novartis Canada/USA, Boehringer Ingelheim (Canada) Ltd, Pfizer Canada, SkyePharma, and KOS Pharmaceuticals. Donald Mahler: Consultant fee, speaker bureau, advisory committee, etc.: The presenting author is a consultant for GlaxoSmithKline, Novartis, and Sunovion, and have served on Advisory Boards for Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pearl, and Sunovion, The C linical Trials Office at Dartmouth-Hitchcock Medical C enter (DHMC ) is currently receiving grants for clinical trials from Boehringer Ingelheim, Novartis, and Sunovion; Donald A. Mahler, M.D. is the DHMC principal investigator for these studies. Tracy White: Employee: Novartis employee Vijay Alagappan: Employee: Novartis employee Hungta Chen: Employee: Novartis employee Karoly Kulich: Employee: Novartis employee Nicola Gallagher: Employee: Novartis employee Donald Banerji: Employee: Novartis employee The following authors have nothing to disclose: Vanessa BrunelClinical trial results of QVA149, combination of two approved products indacaterol and glycopyrronium, will be presented, QVA 149 is in the late stage phase 3 trials prior to approval.